Tricida (TCDA) Tops Q4 EPS by 3c

Tricida (NASDAQ: TCDA) reported Q4 EPS of ($1.09), $0.03 better than the analyst estimate of ($1.12).

“We accomplished a great deal in 2020 but were obviously disappointed that we could not launch veverimer as the first and only FDA-approved treatment for chronic metabolic acidosis in patients with CKD,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “We will now focus on the VALOR-CKD trial to generate additional data prior to the end of 2022.”

Financial Guidance

Tricida currently has the financial resources to fund its operations into at least mid-2022, prior to modifying any of its material agreements. Discussions are ongoing to modify certain of these agreements and, if successful, would extend the company’s financial resources beyond mid-2022. Tricida plans to obtain additional data on the effect of veverimer on (1) CKD progression; (2) physical functioning; and (3) serum bicarbonate within the time frame of our existing capital resources.

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Genco rejects Diana Shipping takeover bid as undervalued
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M